These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38468564)

  • 1. Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
    Asakawa K; Waratani M; Massey O; Holbrook T; Kondo M; Saito A; Nishiyama H
    Int J Urol; 2024 Jul; 31(7):730-738. PubMed ID: 38468564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
    Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
    Hepp Z; Shah SN; Smoyer K; Vadagam P
    J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Kita Y; Otsuka H; Ito K; Hara T; Shimura S; Kawahara T; Kato M; Kanamaru S; Inoue K; Ito H; Igarashi A; Sazuka T; Takamatsu D; Hashimoto K; Abe T; Naito S; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T;
    Int J Urol; 2024 May; 31(5):552-559. PubMed ID: 38303567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
    Morgans AK; Galsky MD; Wright P; Hepp Z; Chang N; Willmon CL; Sesterhenn S; Liu Y; Sonpavde GP
    Urol Oncol; 2023 Aug; 41(8):357.e11-357.e21. PubMed ID: 37208230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
    Gupta S; Andreev-Drakhlin A; Fajardo O; Fassò M; Garcia JA; Wee C; Schröder C
    J Natl Cancer Inst; 2024 Apr; 116(4):547-554. PubMed ID: 38036464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
    Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
    Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
    Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
    Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
    Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    Taguchi S; Kawai T; Nakagawa T; Kume H
    BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Kondo T
    Int J Urol; 2024 May; 31(5):560-561. PubMed ID: 38424666
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Ishihara H; Takagi T
    Int J Urol; 2024 May; 31(5):559-560. PubMed ID: 38366784
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
    Porte F; Granghaud A; Chang J; Kearney M; Morel A; Plessala I; Cawston H; Roiz J; Xiao Y; Solbes MN; Lambert P; Ravaud A; Loriot Y; Thiery-Vuillemin A; Lévy P
    PLoS One; 2024; 19(5):e0302548. PubMed ID: 38728337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.